# Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

> **NCT03604198** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 125 (actual)

## Conditions studied

- Cushing Syndrome

## Interventions

- **DRUG:** relacorilant

## Key facts

- **NCT ID:** NCT03604198
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-07
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604198, "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03604198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*